OSI-906
3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
Molecular Identity
OSI-906
3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
PubChem CID: 11640390
Linsitinib is an imidazopyrazine that is imidazo[1,5-a]pyrazine substituted by 2-phenylquinolin-7-yl, cis-3-hydroxy-3-methylcyclobutyl, and amino groups at positions 1, 3, and 8, respectively. It is dual inhibitor of the IGF-1 receptor and insulin receptor (IC50 = 35 and 75 nM, respectively) that was previously in clinical development for the treatment of cancer and thyroid eye disease. It has a role as an antineoplastic agent, an antimycobacterial drug, an apoptosis inducer and an insulin-like growth factor receptor 1 antagonist. It is a member of cyclobutanes, a member of benzenes, a member of quinolines, a tertiary alcohol, an aromatic amine and an imidazopyrazine.
2D Structure
Properties
C26H23N5O
Molecular Formula
421.50
Molecular Weight
g/mol
421.1903
Exact Mass
Da
4.2
XLogP
Drug-like (Lipinski: < 5)
89.3
TPSA
Good oral absorption (< 140 A²)
2
H-Bond Donors
5
H-Bond Acceptors
663
Complexity
SMILES
Canonical SMILES
SMILES: Synonyms(20)
OSI-906OSI 906RefChem:928309Linsitinib867160-71-2OSI-906 (Linsitinib)Linsitinib(OSI-906)OSI906OSI-906AAASP-74873-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-olMFCD12912153C26H23N5O15A52GPT8TCHEMBL1091644
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to OSI-906
Loading drug network...